Longitudinal relationship between expressed emotion and cannabis misuse in young people with first-episode psychosis

European Psychiatry

Volumn 30, Issue 1, 2015, Pages 20-25

  Gonzalez Blanch C ^a   Gleeson, J F ^b   Cotton, S M ^c,d   Crisp, K ^d   McGorry, P D ^c,d   Alvarez Jimenez, M ^c,d  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

Author keywords

Cannabis; Criticism; Expressed emotion; Families; First episode psychosis; Schizophrenia

Indexed keywords

CANNABIS;

ADULT; ALCOHOL SMOKING AND SUBSTANCE INVOLVEMENT SCREENING TEST; ARTICLE; CANNABIS ADDICTION; CANNABIS USE; CANNABIS-INDUCED PSYCHOSIS; CAREGIVER; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MISUSE; EMOTION; FAMILY LIFE; FAMILY QUESTIONNAIRE; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MALE; MENTAL FUNCTION ASSESSMENT; MENTAL PATIENT; PARENTAL BEHAVIOR ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY ANALYSIS; SOCIAL INTERACTION; YOUNG ADULT; COMPLICATION; DRUG DEPENDENCE; FAMILY; HUMAN RELATION; PSYCHOLOGY; PSYCHOSIS; QUESTIONNAIRE; RISK FACTOR;

ADULT; CAREGIVERS; EXPRESSED EMOTION; FAMILY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERPERSONAL RELATIONS; MALE; MARIJUANA ABUSE; PSYCHOTIC DISORDERS; RISK FACTORS; SUBSTANCE-RELATED DISORDERS; SURVEYS AND QUESTIONNAIRES;

EID: 84920983637     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2014.07.002     Document Type: Article

References (48)

1. Addington J., Addington D. Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatr Scand 2007, 115:304-309.
2. Alvarez-Jimenez M., Gleeson J.F., Cotton S., Wade D., Gee D., Pearce T., et al. Predictors of adherence to cognitive-behavioural therapy in first-episode psychosis. Can J Psychiatry 2009, 54:710-718.
3. Alvarez-Jimenez M., Gleeson J.F., Cotton S.M., Wade D., Crisp K., Yap M.B., et al. Differential predictors of critical comments and emotional over-involvement in first-episode psychosis. Psychol Med 2010, 40:63-72.
4. Alvarez-Jimenez M., Parker A.G., Hetrick S.E., McGorry P.D., Gleeson J.F. Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull 2011, 37:619-630.
5. Alvarez-Jimenez M., Priede A., Hetrick S.E., Bendall S., Killackey E., Parker A.G., et al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res 2012, 139:116-128.
6. Andreasen N.C. Scale for the Assessment of Negative Symptoms (SANS) 1984, University of Iowa, Iowa City, IA.
7. APA Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Press, Washington, DC. Fourth Edition DSM-IV.
8. Archie S., Boydell K.M., Stasiulis E., Volpe T., Gladstone B.M. Reflections of young people who have had a first episode of psychosis: what attracted them to use alcohol and illicit drugs?. Early Interv Psychiatry 2013, 7:193-199.
9. Butzlaff R.L., Hooley J.M. Expressed emotion and psychiatric relapse: a meta-analysis. Arch Gen Psychiatry 1998, 55:547-552.
10. Cannon-Spoor H.E., Potkin S.G., Wyatt R.J. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull 1982, 8:470-484.
11. Clausen L., Hjorthoj C.R., Thorup A., Jeppesen P., Petersen L., Bertelsen M., et al. Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: a 5-year follow-up study of patients in the OPUS trial. Psychol Med 2013, 1-10.
12. Cotton S.M., McCann T.V., Gleeson J.F., Crisp K., Murphy B.P., Lubman D.I. Coping strategies in carers of young people with a first episode of psychosis. Schizophr Res 2013, 146:118-124.
13. Charles V., Weaver T. A qualitative study of illicit and non-prescribed drug use amongst people with psychotic disorders. J Ment Health 2010, 19:99-106.
14. First M., Spitzer R., Williams J., Gibbon M. Structured clinical interview for DSM-IV axis II personality disorders (SCID-II) user's guide and interview 1997, American Psychiatric Press, Washington, DC.
15. Fritz C.O., Morris P.E., Richler J.J. Effect size estimates: current use, calculations, and interpretation. J Exp Psychol Gen 2012, 141:2-18.
16. Ginsberg J. Wechsler test of adult reading. Appl Neuropsychol 2003, 182-184.
17. Gleeson J.F., Cotton S.M., Alvarez-Jimenez M., Wade D., Crisp K., Newman B., et al. Family outcomes from a randomized control trial of relapse prevention therapy in first-episode psychosis. J Clin Psychiatry 2010, 71:475-483.
18. Gleeson J.F., Cotton S.M., Alvarez-Jimenez M., Wade D., Gee D., Crisp K., et al. A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients. J Clin Psychiatry 2009, 70:477-486.
19. Gleeson J.F., Cotton S.M., Alvarez-Jimenez M., Wade D., Gee D., Crisp K., et al. A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients: outcome at 30-month follow-up. Schizophr Bull 2013, 39:436-448.
20. Goldman H.H., Skodol A.E., Lave T.R. Revising axisV for DSM-IV: a review of measures of social functioning. Am J Psychiatry 1992, 149:1148-1156.
21. Gonzalez-Pinto A., Alberich S., Barbeito S., Gutierrez M., Vega P., Ibanez B., et al. Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull 2011, 37:631-639.
22. Green B., Kavanagh D.J., Young R.M. Reasons for cannabis use in men with and without psychosis. Drug Alcohol Rev 2004, 23:445-453.
23. Gregg L., Barrowclough C., Haddock G. Reasons for increased substance use in psychosis. Clin Psychol Rev 2007, 27:494-510.
24. Gregg L., Haddock G., Barrowclough C. Self-reported reasons for substance use in schizophrenia: a Q-methodological investigation. Mental health and substance use 2009, 24-39.
25. Hides L., Cotton S.M., Berger G., Gleeson J., O'Donnell C., Proffitt T., et al. The reliability and validity of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in first-episode psychosis. Addict Behav 2009, 34:821-825.
26. Hides L., Dawe S., Kavanagh D.J., Young R.M. Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. Br J Psychiatry 2006, 189:137-143.
27. Hooley J.M. Expressed emotion and relapse of psychopathology. Annu Rev Clin Psychol 2007, 3:329-352.
28. Kazarian S.S., Malla A.K., Cole J.D., Baker B. Comparisons of two expressed emotion scales with the Camberwell family interview. J Clin Psychol 1990, 46:306-309.
29. King S., Dixon M.J. Expressed emotion and relapse in young schizophrenia outpatients. Schizophr Bull 1999, 25:377-386.
30. Kolliakou A., Joseph C., Ismail K., Atakan Z., Murray R.M. Why do patients with psychosis use cannabis and are they ready to change their use?. Int J Dev Neurosci 2011, 29:335-346.
31. Koskinen J., Lohonen J., Koponen H., Isohanni M., Miettunen J. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull 2010, 36:1115-1130.
32. Kuipers E., Bebbington P., Dunn G., Fowler D., Freeman D., Watson P., et al. Influence of carer expressed emotion and affect on relapse in non-affective psychosis. Br J Psychiatry 2006, 188:173-179.
33. Linszen D.H., Dingemans P.M., Nugter M.A., Van der Does A.J., Scholte W.F., Lenior M.A. Patient attributes and expressed emotion as risk factors for psychotic relapse. Schizophr Bull 1997, 23:119-130.
34. Lobbana F., Barrowclough C., Jeffery S., Bucci S., Taylor K., Mallinson S., et al. Understanding factors influencing substance use in people with recent onset psychosis: a qualitative study. Soc Sci Med 2010, 70:1141-1147.
35. Lukoff D., Liberman R.P., Nuechterlein K.H. Symptom monitoring in the rehabilitation of schizophrenic patients. Schizophr Bull 1986, 12:578-602.
36. Montgomery S.M. Depressive symptoms in acute schizophrenia. Prog Neuropsychopharmacol 1979, 3:429-433.
37. Mueser K.T., Drake R.E., Wallach M.A. Dual diagnosis: a review of etiological theories. Addict Behav 1998, 23:717-734.
38. Newcombe D.A., Humeniuk R.E., Ali R. Validation of the World Health Organization Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): report of results from the Australian site. Drug Alcohol Rev 2005, 24:217-226.
39. Portney L.G., Watkins M.P. Foundations of clinical research: applications to practice 2000, Prentice-Hall, Upper Saddle River, NJ. 2nd ed.
40. Pourmand D., Kavanagh D.J., Vaughan K. Expressed emotion as predictor of relapse in patients with comorbid psychoses and substance use disorder. Aust N Z J Psychiatry 2005, 39:473-478.
41. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990, 264:2511-2518.
42. Rothman K.J. No adjustments are needed for multiple comparisons. Epidemiology 1990, 1:43-46.
43. Spencer C., Castle D., Michie P.T. Motivations that maintain substance use among individuals with psychotic disorders. Schizophr Bull 2002, 28:233-247.
44. Vaughn C., Leff J. The measurement of expressed emotion in the families of psychiatric patients. Br J Soc Clin Psychol 1976, 15:157-165.
45. WHO The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction 2002, 97:1183-1194. ASSIST Working Group.
46. Wiedemann G., Rayki O., Feinstein E., Hahlweg K. The family questionnaire: development and validation of a new self-report scale for assessing expressed emotion. Psychiatry Res 2002, 109:265-279.
47. Wisdom J.P., Manuel J.I., Drake R.E. Substance use disorder among people with first-episode psychosis: a systematic review of course and treatment. Psychiatr Serv 2011, 62:1007-1012.
48. Zammit S., Moore T.H., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry 2008, 193:357-363.